Treatment-Free Survival Can Be a Meaningful Endpoint in Clinical Trials
Researchers and clinicians should consider treatment-free survival when analyzing the results of clinical trials, according to one expert.
Related Articles
FDA Approves Subcutaneous Use of Atezolizumab and Hyaluronidase-tqjs
The agency approved the subcutaneous injection of atezolizumab and hyaluronidase-tqjs for all of the adult indications as the intravenous formulation of atezolizumab.
Innovative Program Reduces Nurse Turnover and Fosters Development
The US Oncology Network (The Network) has developed one of the most comprehensive programs in the nation to support the professional development and retention of…
Ruxolitinib May Elicit Skin/Joint, Chronic GVHD Responses
The use of ruxolitinib presented improved rates of skin/joint responses, cGVHD responses, patient-reports, low NRM, and high FFS in patients with refractory sclerotic cGVHD.
Connecting Patients With Multiple Myeloma to Larger Institutions for CAR T-Cell Therapy
Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell therapy treatment.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck…
Nurse-led High Risk Referral Protocol Improves Risk Communications During Mammography Appointments
Increased use of consultations, breast MRIs, genetic counseling, and other testing in high-risk patients were a direct result from nurse-led high risk referral protocols.
Complex Multidisciplinary Care of an AYA With Ewing Sarcoma
This case demonstrates the pivotal role of a cohesive multidisciplinary team in navigating the complex care of oncology patients from diagnosis, treatment, and posttreatment surveillance.
Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care teams should still focus on multidisciplinary approaches…
The Changing Landscape of Clinical Trials in Cancer Care
Although excitement surrounds the constantly changing landscape of cancer care, we have much to learn to keep our practices current.
BCMA/CD19–Targeting CAR T-Cell Therapy Safely Produces Favorable Outcomes in Newly Diagnosed Multiple Myeloma
GC012F, a BCMA/CD19–targeted CAR T-cell therapy, safely produced favorable outcomes in patients with newly diagnosed multiple myeloma after induction therapy.